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Abstract
Background
Immunoglobulin G (IgG) is an essential plasma-derived medicine that is lacking in develop-
ing countries. IgG shortages leave immunodeficient patients without treatment, exposing
them to devastating recurrent infections from local pathogens. A simple and practical meth-
od for producing IgG from normal or convalescent plasma collected in developing countries
is needed to provide better, faster access to IgG for patients in need.
Methodology/Principal Findings
IgG was purified from 10 consecutive minipools of 20 plasma donations collected in Egypt
using single-use equipment. Plasma donations in their collection bags were subjected to
5%-pH5.5 caprylic acid treatment for 90 min at 31°C, and centrifuged to remove the precipi-
tate. Supernatants were pooled, then dialyzed and concentrated using a commercial dispos-
able hemodialyzer. The final preparation was filtered online by gravity, aseptically dispensed
into storage transfusion bags, and frozen at<-20°C. The resulting preparation had a mean
protein content of 60.5 g/L, 90.2% immunoglobulins, including 83.2% IgG, 12.4% IgA, and
4.4% IgM, and residual albumin. There was fourfold to sixfold enrichment of anti-hepatitis
B and anti-rubella antibodies. Analyses of aggregates (<3%), prekallicrein (5-7 IU/mL), plas-
min (26.3 mU/mL), thrombin (2.5 mU/mL), thrombin-like activity (0.011 U/g), thrombin genera-
tion capacity (< 223 nM), and Factor XI (<0.01 U/mL) activity, Factor XI/XIa antigen
(2.4 ng/g) endotoxin (<0.5 EU/mL), and general safety test in rats showed the in vitro safety
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Conclusions/Significance
90% pure, virally-inactivated immunoglobulins can be prepared from plasma minipools
using simple disposable equipment and bag systems. This easy-to-implement process
could be used to produce immunoglobulins from local plasma in developing countries to
treat immunodeficient patients. It is also relevant for preparing hyperimmune IgG from con-
valescent plasma during infectious outbreaks such as the current Ebola virus episode.
Author Summary
Plasma-derived immunoglobulin G (IgG) is on WHO’s Essential Medicines List, yet devel-
oping countries face severe shortages of this critical treatment. Infusion of IgG prepared
from locally-collected plasma provides an advantageous mix of antibodies to viral and bac-
terial pathogens found in the living environment, and this can reduce recurrent infections
in immune-deficient patients. We developed a simple manufacturing process using dispos-
able equipment (blood bags, hemodialyzer, and filters) to isolate immunoglobulins from
minipools of 20 plasma donations. This process yields a ca. 90% pure virally-inactivated
immunoglobulin fraction at 50–60% recovery. Anti-hepatitis B and anti-rubella immuno-
globulins were enriched fourfold to sixfold. The product was free of in-vitro thrombogenic
and proteolytic activity, confirming its expected clinical safety profile. Virus validations
showed caprylic acid treatment robustly inactivated or removed infectivity of lipid-
enveloped viruses, including human immunodeficiency virus (HIV) and hepatitis C virus
model. This simple and cost-effective process is implemented in Egypt to prepare experi-
mental batches for clinical evaluation. It can enhance immunoglobulin supplies to treat
immunodeficient patients through passive transmission of antibodies directed against
local pathogens. The method requires minimal training and reasonable infrastructure, and
is a practical means to prepare convalescent hyperimmune IgG during infectious out-
breaks such as the current Ebola episode.
Introduction
Plasma products to treat congenital bleeding and immunological diseases are made in industri-
alized countries using complex technologies unavailable in the developing world [1]. Low- to
medium-income countries may have little or no access to these life-saving products; these na-
tions urgently need practical processing methods to produce them affordably. We have intro-
duced the concept of small-scale (“minipool”) plasma processing methods implementable with
minimum infrastructural requirements. We developed viral inactivation and protein purifica-
tion technologies in single-use equipment to prepare virally safe solvent/detergent-filtered
(S/D-F) plasma for transfusion as well as minipool S/D-F cryoprecipitate to treat bleeding dis-
orders [2–4]. Similarly simple technologies are desperately needed to make safe immunoglobu-
lin G (IgG), a product on the Essential Medicine List of the World Health Organization, to
treat immune-deficient patients. Thus we describe here a small-scale caprylic acid IgG fraction-
ation process that requires minimal capital investment and uses disposable equipment. This
production approach could increase the supply of IgG in developing countries and improve
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treatment of immunodeficient patients. It is also a realistic approach to consider in the prepa-
ration of convalescent immunoglobulins during infectious outbreaks such as the current Ebola
virus epidemic [5,6].
Methods
Plasma Preparation
Whole blood was collected with CPD-A anticoagulant/preservative solution (ratio: 14ml/100ml
of blood) from regular volunteer non-remunerated donors at Shabrawishi Hospital Blood Bank
(Giza, Cairo, Egypt). Donors received information prior to donation in compliance with national
regulations. The procedure was approved by the Institutional Review Board from Cairo Univer-
sity (Number N-5–2014). The blood bank is licensed (license number N°7) by the General Direc-
torate for Blood Transfusion Affairs, Ministry of health and is ISO certified (ASR number 1230).
Non-leuco-reduced blood was centrifuged at 3600x g for 12 minutes within 4 hours of col-
lection. Plasma was transferred into storage bags, frozen in a -40°C freezing room, and stored
at-25°C for a maximum of 12 months.
Minipool IgG Fractionation
The preparation of the IgG fraction is summarized in Fig. 1. Plasma from 20 blood donations
tested for anti-A and anti-B titer< 32 (Micro Typing Cards with NaCl; DiaMed AG, Cressier
sur Morat, Suisse), or from the same blood group, were subjected to in-bag cryoprecipitation
[2,7]. The cryoprecipitate-poor supernatant (approximately 200mL) was transferred into
a transfusion bag, frozen and stored at<-30°C. Supernatants were thawed at 30–35°C. After
thawing, caprylic acid (Merck, Darmstadt, Germany) was added within one minute to each bag
under constant manual stirring to 5% (v/v) final concentration, pH 5.5 +/- 0.1, and the mixture
incubated at 31+/- 0.5°C for 90 minutes at 150 rpm in a temperature-controlled shaker-
incubator (Lab Therm LT-W, Kühner, Switzerland) [2]. Precipitated proteins were removed by
centrifugation (KR4i, Jouan, St Herblain, France) at 3500x g for 45 minutes. The clear superna-
tants (approximately 2.8 L) were pooled under laminar flow into a SD Virus Inactivation Bag
Cascade (VIPS SA, Colombier, Switzerland) and concentrated (typically 60 g/L) using a sterile
single-use hemodialyzer (F6HB, Fresenius, Bad Homburg, Germany), a hemodialysis pump
and monitoring equipment (Terumo BCT, Lakewood, CO, United States). The solution was
progressively diluted with 5 volumes of sterile pyrogen-free saline solution and subjected to
diafiltration to remove caprylic acid and concentration. The Ig fraction was centrifuged
(Jouan) at 3500x g for 45 minutes at 2–4°C to remove any particulates, then filtered by gravity
through a pyrogen-free pharmaceutical-grade BC0025L60SP03A cartridge (3M Cuno, Cergy-
Pontoise, France) and a 0.2 μmMini-Kleenpak sterilizing filter (Pall Corporation, Dreieich,
Germany) and directly dispensed under laminar flow into sterile plastic storage bags and stored
frozen at<-25°C.
Protein Characterization and Purity Profile
Total protein was determined by Biuret (Protein Kit 110307, Merck Millipore, MA, USA).
Zone electrophoresis was performed on agarose gels (Hydragel 7 protein kit, Sebia, Evry,
France), staining with amidoblack and densitometric analysis by a semi-automated Hydrasys
instrument (Sebia). Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE),
under non-reducing and reducing conditions, used 4%~12% Bis-Tris Gel (NuPAGE, Novex
Life Technologies, CA, USA) as before [8]. Albumin was measured photometrically using bro-
mocresol green (DiaSys Diagnostic Systems, Holzheim, Germany). IgG, IgA, and IgM were
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determined by immunoturbidimetry [9]. Anti-hepatitis B and anti-rubella immunoglobulins
G titres were determined using Architect Anti-HBs Reagent and Architect Rubella IgG reagent,
respectively (Abbott Laboratories, North Chicago, IL, USA). Molecular size distribution was
analyzed by size exclusion chromatography on a TSKGel G3000SWXL column (7.8mm ID
X 30 cm L) protected with a TSKGel guard column (6.0mm ID X 4.0 cm L), equipped with iso-
cratic pump model SDS 9414, UV-VIS detector model S3210, Rhiodyne manual injector and
PeakSimple Chromatography Data System SRI Model333 as data integrator (Schemback,
Fig 1. Preparation scheme of the IgG-enriched plasma fraction.
doi:10.1371/journal.pntd.0003501.g001
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Germany). The mobile phase was 0.1 M sodium sulfate, 50 mM sodium acetate, 0.05% sodium
azide, pH5, flow-rate was 0.5 ml/min, and the detection wavelength was 280nm. Thrombin
generation assay (TGA) used Technothrombin fluorogenic substrate and RC High reagent
(Technoclone, Vienna, Austria), and prekallikrein activator (PKA), plasmin, thrombin,
thrombin-like amidolytic activities used S-2302, S-2251, S-2238, and S-2288 chromogenic pro-
tease substrates (Chromogenix, Milan, Italy), respectively [10]. Factor XI coagulant activity
was measured by one-stage thromboplastin time coagulation assay with human factor
XI—deficient and reference plasma (DiaMed, Cressier, Switzerland), and FXI/FXIa antigen
with Human Factor XI quantitative sandwich ELISA (Abcam, Cambridge, UK) as before [10].
Endotoxins were determined by the LAL assay. A licensed human IgG preparation produced
by a combined ethanol fractionation-chromatography process was used as a control. Data are
expressed as the mean ± standard deviation.
Caprylic Acid
The 0.5-mL samples were mixed with 1mL ice-cold methanol and incubated overnight in
a deep freezer at -80°C. Samples were centrifuged at 4000x g for 20 minutes and 1 mL of the su-
pernatant was taken and filtered through a 0.45μm syringe filter to a 1.5 ml clean tube. Samples
were processed and analyzed by HPLC (Schemback SFD GmbH, Bad Honnef, Germany)
equipped with analytical pump (SFD 9414), UV/VIS detector (S 3210), Rheodyne manual in-
jector model 7725i, Peak Simple Data System model 333 (SRI, Torrance, California, USA), and
Luna 5u, C8(2) 100Å (150 mm x 4.6 mm) column chromatography (Phenomenex, Torrance,
USA); 0.1% trifluoroacetic acid (TFA) in a 80:20 mixture of methanol (Fisher Scientific, UK)
and water was used as mobile phase at 0.8 mL/min. Caprylic acid detection was done at
214nm wavelength
Di (2-ethylhexyl) Phthalate (DEHP) Assay
Di (2-ethylhexyl) phthalate (DEHP) was assessed on the starting plasma and final IgG. Samples
were processed and analyzed as before [2] by HPLC (Schemback SFD GmbH, Bad Honnef,
Germany) equipped with analytical pump (SFD 9414), UV/VIS detector (S 3210) at a wave-
length of 202 nm, using a Lichrospher 100 RP 18–5μ (250 mm x 4.6 mm) column (CS-
Chromatographie Service GmbH, Langerwehe, Germany). A mixture of 85:15 of acetonitrile
and methanol (Merck) was used as mobile phase at 1.5 mL/min for 8 minutes analysis time.
Viral Reduction Studies
The capacity of the caprylic acid treatment to inactivate/remove viruses was assessed at Texcell
(Evry, France), a specialized laboratory working under GLP compliance awarded by the
ANSM, France’s National Agency for Medicines and Health Products Safety. The process was
scaled-down by a factor of 10 (40 mL). Validations were performed in duplicate under
worst-case conditions using cryo-poor plasma as starting material, 4.8% caprylic acid, and
a temperature of 28.5–30.5°C. The study followed Good Laboratory Practices and CPMP rec-
ommendations [11]. Plasma tested negative for HBsAg; HIV-1/HIV-2 Ab+P24 Combo assay;
Anti-HCV by Abbott Architect Chemiluminescence (Abbott Laboratories); HBV, HIV and
HCV individual-donor-Nucleic Acid Test (NAT) (Tigris; Grifols Diagnostic Solutions Inc.,
Emeryville, CA, USA) using the Procleix Ultrio assay. Cryo-poor plasma samples were pre-
pared at the Shabrawishi Hospital Blood bank, frozen at -30°C and shipped with dry ice to Tex-
cell. HIV-1 (Lai strain), bovine viral diarrhoea virus (BVDV; NADL strain; ATCC VR-534),
and pseudorabies virus (PRV; Aujeszky disease virus; Kojnock strain; ATCC VR-135) were
used for spiking, and P4-CCR5, MDBK cell lines (ATCC CCL-22) and Vero (Molecular
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Virology Laboratory, Institut Pasteur, Paris, France), respectively, for titration assays. Cryo-
poor plasma was transferred into the reaction container. When temperature reached
28.5–30.5°C, the material was spiked with virus-inoculum (2.0% [v/v]). Spiked starting materi-
al was homogeneized and positive controls were collected; 4.8% (v/v; final concentration) ca-
prylic acid was added in less than one minute. The spiked solution was kept at 28.5–30.5°C
under continuous transversal agitation. Samples were taken right after caprylic acid addition
(T0) and at 15, 45, 60, and 120 minutes after, and were immediately centrifuged at 3500x g for
45 minutes at 4°C. Supernatants were recovered and diluted 30 folds (BVDV) or 50 folds (PRV
and HIV) with culture medium to stop the reaction, and were frozen and stored at -70°C. Con-
trol samples prepared under these conditions were verified not to induce cellular toxicity.
Spiked samples were titrated by validated end-point dilution assay, and the viral clearance of
the steps was assessed in terms of infectivity. Viral titers were calculated and expressed as
50% tissue culture infective dose per milliliter (TCID50/mL) using the Sperman Kaber formula.
Infectious titers were calculated at the non-interfering dilution after large volume titration.
General Safety Tests
The safety of the purified IgG was evaluated in Sprague—Dawley rats as described before [2],
after approval from the National Cancer Institute (Cairo, Egypt), where the study was per-
formed. It was conducted according to institution guidelines on animal studies and following
recommendations specified in the Code of Federal Regulations Title 21, except that the injec-
tion was done intravenously, not intraperitonally, and the observation period was 14 days in-
stead of 7. Twenty-one healthy rats weighing 80–100 g and not used previously for any test
purpose were divided into three groups of seven rats. Animals received a dose of 6.5 mL/kg of
saline, commercial IgG (control) or minipool IgG. The rats were observed once daily for abnor-
mal behavior or clinical signs. Body weight, and consumption of water and food was recorded
at 10 time-points over the observation period. The study was only observational and did not re-
quire anesthesia, sacrifice nor dissection.
Results
The main characteristics of the final preparations are summarized in Table 1. The product was
clear, with a slight bluish color, and not turbid. Sodium content and osmolality were close to
physiological value. Mean protein concentration was 60.2 g/L, with a content of gamma-
globulins close to 90%, and traces of albumin, alpha-1, alpha-2, and bêta-proteins revealed by
zone electrophoresis (Fig. 2A and B). The relative abundance of IgG was 82–85%, IgA 11–13%,
and IgM 4–5%, close to the physiological proportion. Albumin was less than 3 g/L. Content of
high molecular weight proteins/aggregates was less than 3% and monomers and dimers more
than 90% by HPLC. Anti-A and anti-B isoagglutinin titer in all batches was less than 1/32.
Titer of anti-hepatitis B and anti-rubella immunoglobulin G showed enrichment factors com-
pared to plasma of 5.8 and 4.1, respectively. Proteolytic and thrombogenic activity were also as-
sessed. Mean PKA was 6.1 ± 1.1 IU/ml (control: 3 IU/ml), well below the maximum limit of
35 IU/ml in the European Pharmacopoeia. TGA data showed a peak thrombin of 0–223 nM
(control: 56.8 nM) below the threshold value of 350nM associated with thromboembolic activi-
ty in some IVIG preparations. Mean plasmin was 26.3 mU/mL (control: 20.3 mU/mL), throm-
bin 2.5 mU/mL (control: 24 mU/mL), thrombin-like proteolytic activity 0.011 U/g protein
(control: 0.06 U/g protein), Factor XI activity< 0.01 IU/mL, and Factor XI/XIa 2.4 ng/g pro-
tein. SDS-PAGE (Fig. 3) under non-reducing conditions (A) evidenced that most proteins mi-
grated at a MW close to 150–160 kDa (immunoglobulins G and A). Minor protein bands were
detected at MW close to 25, 60, and 80–90 kDa. Under reducing conditions (B), two major
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protein bands with MW of 50 and 25 kDa (immunoglobulin G heavy and light chains, respec-
tively) were detectable. The minipool IgG pattern was similar to control apart for additional
protein bands with MW of approximately 150–160, 90, and 70kDa under reducing conditions.
Caprylic acid in the final preparation was<750ppm, and DEHP<5ppm. Endotoxin content
was less than 0.5 EU/ml.
Viral validation data (Table 2) showed that (a) viral infectivity was not affected after spiking to
the starting material, and (b) HIV-1, BVDV, and PRV inactivation was fast and complete within
15 minutes after caprylic acid addition. Reduction factors (duplicate experiments) were> 5.69
and> 5.74 log for HIV-1,> 5.23 and> 5.35 log for BVDV, and> 5.10 and>5.10 log for PRV.
General safety tests did not induce rat mortality nor behavioral changes in the three groups and
there was no significant difference in body weight increase rate over 7 days (Table 3). The water
and food consumption was not noticeably different among the three groups, ranging between
4–13% and 9–14% of total available, respectively, over the 14 days of observation post infusion.
Table 1. Properties and speciﬁcations (or range) of the IgG-enriched plasma fraction.
Parameters Results Method
Formulation Frozen -
Appearance Clear, bluish, no visible particles* Visual observation
pH 5.4–5.6* pH meter
Na, mmol/L 148.2 +/- 1.6* Chemical analyzer
K, mmol/L 2.4 +/- 0.1* Chemical analyzer
Osmolality, mosm/kg 295 +/- 15* Osmometer
Total proteins, g/L 60.5 ± 16.7** Biuret
Gamma globulins, % 90.2±2.8** Zone electrophoresis
Immunoglobulin repartition
IgG, % 83.2 ± 1.1** Immunoturbidimetry
IgA, % 12.4 ± 1.0** Immunoturbidimetry
IgM, % 4.4 ± 0.6** Immunoturbidimetry
Albumin, g/L < 3* Bromocresol green
Aggregates, % < 3* HPLC
Monomers and dimers, % > 90%* HPLC
Anti-A/Anti-B, titer < 1/32* Micro-typing
Anti-HBs, mIU/mL (enrichment factor) 330 +/- 421 (5.8 +/- 2.7)* Architect, Abbott
Anti-rubella, mIU/ml (enrichment factor) 322. 1 +/- 111.9 (4.1 +/- 1.3)* Architect, Abbott
PKA, IU/mL (3% protein concentration) 6.1 ± 1.1** S-2302**
Thrombin generation, peak thrombin, nM <350 (0–223)** Technothrombin assay, RC high reagent
Plasmin, mU/mL 26.3 ± 2.4** S-2251
Thrombin, mU/mL 2.5 ± 2.4** S-2238
Thrombin-like activity, U/g 0.011 ± 0.008** S-2288
Factor XIc IU/mL < 0.01* Coagulation assay
Factor XI/XIa Ag, ng/g protein 2.4 ± 0.9** Sandwich ELISA
Caprylic acid, μg/mL < 750* HPLC
DEHP, ppm < 5* HPLC
Endotoxin, EU/ml < 0.5** LAL test
Sterility Pass* Sterility test (growth medium)
* N = 10;
** N = 5 (consecutive batches)
doi:10.1371/journal.pntd.0003501.t001
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Discussion
Polyvalent IgG, the leading plasma product [12], is manufactured from thousands of liters of
US or European plasma pools fractionated in highly sophisticated facilities using complex and
highly regulated large-scale technologies [1,13]. This IgG product is in short supply and has
a mix of antibodies that is not adapted to the treatment of patients in tropical areas, who are ex-
posed to different pathogens. It is therefore crucial to develop small-scale, easy-to-use technol-
ogies adapted to process the plasma available in non-Western countries. We show here that
a minipool human IgG-enriched fraction can be prepared using a simple process run in dispos-
able CE-marked equipment. The technique relies on caprylic (octanoic) acid precipitation of
non-Ig molecules [14,15]. Caprylic acid is already used to prepare licensed IgG or IgM prepara-
tions from precipitates II+III [16,17], II [18], or III [18]; 5%-pH 5.5 caprylic acid precipitation
is also used to produce horse plasma-derived therapeutic antivenom immunoglobulins [19,20],
and this process may become an alternative to chromatography for monoclonal antibodies pro-
duction [21].
The minipool Ig fraction contained approximately 90% Ig, with a ratio of IgG/IgA/IgM sim-
ilar to plasma. The content in IgA does not constitute a risk for primary immunodeficient
Fig 2. Zone electrophoresis. A: Patterns of 5 consecutive batches of minipool IgG-enriched plasma
fractions (Minipool IgG batches B1 to B5) and control IgG (C) showing the separation between albumin (Alb)
and alpha-1 (α-1), alpha-2 (α-2), bêta- (β) and gamma- (γ) proteins. B: densitographic analysis showing the
percentage (%) of albumin, alpha-1, alpha-2, bêta, and gamma proteins in 5 batches (B1–B5) of minipool
IgG. Control: control IgG.
doi:10.1371/journal.pntd.0003501.g002
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Fig 3. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Patterns of 10 consecutive batches
of minipool IgG-enriched plasma fractions (Minipool IgG batches B1 to B10) and control IgG (C) under non-
reducing (A) or reducing (B) conditions. Control: control IgG; IgG: immunoglobulin G; Alb: albumin. MW:
molecular weight markers (kDa).
doi:10.1371/journal.pntd.0003501.g003
Table 2. Log removal factors of HIV-1, BVDV, and PRV during caprylic acid treatment (duplicate
experiments).
Virus HIV BVDV PRV
Strain Lai NADL Kojnock
Infectious titer in spiked starting material*
Run A 2.35 x 106 1.31 x 107 2.88 x 106
Run B 2.79 x 106 1.73 x 107 2.88 x 106
Infectious titer after caprylic acid treatment*
Run A < 4.86** < 7.72 x 101** < 2.28 x 101**
Run B < 4.86** < 7.72 x 101** < 2.28 x 101**
Mean reduction factor (log 10)
Run A >5.69 >5.23 >5.10
Run B >5.74 >5.35 >5.10
*Viral titers are expressed as TCID50/mL.
**Infectious titers at the non-interfering dilution after large volume titration.
doi:10.1371/journal.pntd.0003501.t002
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patients who cannot develop anti-IgA. The preparation should not be infused to IgA-deficient
patients, although such risks were recently highlighted as being not evidence-based in
many patients [22]. Residual proteins included albumin, alpha-1, alpha-2, and bêta-proteins.
Aggregate content was low (below 3%) in compliance with requirements for commercial intra-
venous IgG. It is important to ensure that the anti-A /-B titers of the minipool IgG is consis-
tently low, especially in a situation where the preparation would be used in hematologically
challenged recipients, as is the case of Ebola patients. All batches prepared here had a titer
below 1:32, less than the limit of 1:64 in the European Pharmacopeia. One means to reduce
the ABO isoagglutinin titer is to mix plasma donations for each batch based on a ratio of
30% group A, 30% group B, 20% group AB and 20% group O, an approach already done for
a universal pooled plasma for transfusion [23]. Another means we have now implemented is
the preparation of minipool IgG from specific blood group plasma donations allowing transfu-
sion to matched blood group patients. The preparation was free of proteolytic activity and had
PKA levels within European Pharmacopoeia limits. Recent thromboembolic events associated
with intravenous or sub-cutaneous IgG [24,25] prompted us to check most particularly for pro-
coagulant markers [26] especially in situations when such minipool Ig preparation would be
used in individuals (e.g. ebola patients) experiencing disseminated intravascular coagulation.
Results using TGA, the current preferred assay for assessing the thrombogenicity of IgG
[25,27,28], chromogenic substrates for thrombin and thrombin-like activity, and ELISA and
coagulant assays to detect FXI and FXIa strongly suggested that the preparation is devoid of
relevant in vitro thrombogenic and proteolytic activity. Previous spiking experiments using
cryoprecipitate-poor plasma had shown that 5%-pH5.5 caprylic acid incubation inactivates/
precipitates FXI/FXIa [9], confirming our findings. We could not assess Fc fragment integrity
and anticomplementary activity, but the fact that immunoglobulins are not precipitated during
the whole procedure argues in favor of unlikely molecular alteration and aggregation [12]. The
disposable hemodialyzer was effective in removing caprylic acid to undetectable levels. It may
also contribute to removal of DEHP plasticizer, together with the adsorption filter used prior
to sterile filtration and dispensing, as previously found for a charcoal filter [2].
Viral safety of the preparation relies on proper donor screening, serological testing of dona-
tions [29,30] and, when feasible, single-donor multiplex NAT testing for HIV, HBV and HCV
[31], as was done in this research. Most importantly, manufacturing processes should include
one or two dedicated viral inactivation steps, a major tripod of viral safety [30,32]. Caprylic
acid treatment is known to be a robust viral reduction treatment for both human [16,18,33]
Table 3. Percent increase in body weight of rats (3 groups of 7 rats) treated with saline, commercial IgG, or minipool IgG.
Treatment Control Commercial IgG Minipool IgG
Period (day) Mean ± SD Mean ± SD Mean ± SD
1 19.29 10.58 7.57 16.92 11.43 6.27
2 24.29 15.03 11.57 17.70 16.00 7.87
5 35.86 13.33 26.00 19.58 31.43 7.59
6 30.00 16.67 18.14 20.91 18.14 7.90
7 35.14 15.23 26.14 16.45 27.57 9.52
8 41.71 15.84 26.00 20.18 32.00 8.77
9 43.29 15.96 24.14 21.67 33.00 9.93
12 47.14 18.21 25.71 13.78 34.86 8.86
13 48.57 18.06 35.00 19.16 39.71 10.00
14 52.14 20.41 38.86 22.43 42.43 9.62
doi:10.1371/journal.pntd.0003501.t003
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and horse-derived IgG [34,35]. Our study confirms that at the concentration and pH used in
this work, this is highly effective against lipid-enveloped viruses, as> 4 log of HIV, BVDV and
PRV were inactivated within 15 minutes of treatment. Implementing a pH4 incubation step is
readily possible as a second inactivation step for lipid-enveloped viruses [30]. The small size of
the pool (20 donations) and the neutralizing activity of potential antibodies against hepatitis
E or A (HAV) viruses and parvovirus B19 reduce the risks from non-enveloped viruses. Al-
though we did not perform such evaluation, some removal of non-enveloped viruses may
occur during caprylic acid precipitation, as reported for parvovirus and HAV by others
[16,17,36]. In addition, dedicated virus removal by 20–35nm nanofiltration, as well as duplex
nucleic acid testing for HAV and Parvovirus B19 could be considered to improve the safety
margin, especially if larger batches are produced, to make these additional steps more cost-
effective [37]. Reproducible IgG recovery (55–65%, corresponding to about 4.5 to 5 g of IgG/L
plasma) was achieved, consistent with recovery of antivenom immunoglobulins from horse
plasma [19].
This process could be implemented readily in blood establishments or national service cen-
ters after appropriate operator training and basic equipment acquisition. The caprylic acid
treatment is performed in a closed-bag system under continuous gentle transversal agitation in
a thermostated shaker incubator. Laminar flow cabinets are used for additions of reagents to
protect against bacterial contamination. Blood bank centrifuges are used for centrifugation.
Concentration of IgG and caprylic acid removal are done using commercially available single-
use pyrogen-free hemodialyzer. These devices are easy to use, do not present cleaning-related
cross-contamination risks, and are affordable (about US$10 per unit). IgG concentration and
dialysis fraction is fast (typically 120 minutes to concentrate 3.1 to 3.2 L of supernatant IgG,
and 90 minutes to perform 5 dialysis cycles), and yields a clear solution free of particles. The
bluish color is typical of processes using caprylic acid and is likely due to the presence of residu-
al ceruloplasmin [38]. The resulting concentrate is clarified by simple gravity, without pumps,
on a pyrogen-free single-use adsorptive filter connected online to a sterilizing 0.2μm filter, as is
also done for S/D-F plasma and S/D-F cryoprecipitate [2]. The process can use whole plasma,
cryoprecipitate-poor plasma or prothrombin complex-depleted cryoprecipitate-poor plasma
[39] thanks to the robustness of the 5%/pH 5.5 caprylic acid step to precipitate non-Ig proteins
[19]. Thus, the process does require training and basic equipment and facility, but is more fea-
sible than current fractionation technologies for implementation in low or medium
income countries.
The enrichment factor found for the two specific immunoglobulins monitored (anti-hepatitis
B and anti-rubella IgG) shows the capacity of the process to concentrate hyperimmune IgG. This
shows the feasibility of applying this production concept to the preparation of IgG from conva-
lescent plasma. This purification/viral inactivation process, based on small volume and disposable
equipment, could be ideal for the preparation of hyperimmune IgG from convalescent plasma in
infectious outbreaks, as seen currently inWest African countries exposed to the Ebola virus [6,40].
Conclusion
Producing a 90% pure immunoglobulin fraction in disposable, single-use devices is feasible.
This method could be used to produce immunoglobulins from local plasma in developing
countries to protect immunodeficient patients against infectious agents, and could be of
interest for preparing hyperimmune IgG from convalescent plasma collected during infec-
tious outbreaks such as the current Ebola virus episode. Clinical evaluations of this prepara-
tion in immunodeficient children are on-going and indicate good tolerance and normal
IgG half-life.
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